268 related articles for article (PubMed ID: 27210749)
1. Oncogenic BRAF-Mediated Melanoma Cell Invasion.
Lu H; Liu S; Zhang G; Kwong LN; Zhu Y; Miller JP; Hu Y; Zhong W; Zeng J; Wu L; Krepler C; Sproesser K; Xiao M; Xu W; Karakousis GC; Schuchter LM; Field J; Zhang PJ; Herlyn M; Xu X; Guo W
Cell Rep; 2016 May; 15(9):2012-24. PubMed ID: 27210749
[TBL] [Abstract][Full Text] [Related]
2. Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness.
Meng P; Bedolla RG; Yun H; Fitzpatrick JE; Kumar AP; Ghosh R
Mol Carcinog; 2019 Sep; 58(9):1701-1710. PubMed ID: 31124185
[TBL] [Abstract][Full Text] [Related]
3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
4. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
6. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
7. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the functional domain requirements of cortactin in invadopodia formation.
Webb BA; Jia L; Eves R; Mak AS
Eur J Cell Biol; 2007 Apr; 86(4):189-206. PubMed ID: 17343955
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance.
Li S; Song Y; Quach C; Guo H; Jang GB; Maazi H; Zhao S; Sands NA; Liu Q; In GK; Peng D; Yuan W; Machida K; Yu M; Akbari O; Hagiya A; Yang Y; Punj V; Tang L; Liang C
Nat Commun; 2019 Apr; 10(1):1693. PubMed ID: 30979895
[TBL] [Abstract][Full Text] [Related]
10. Functional RET G691S polymorphism in cutaneous malignant melanoma.
Narita N; Tanemura A; Murali R; Scolyer RA; Huang S; Arigami T; Yanagita S; Chong KK; Thompson JF; Morton DL; Hoon DS
Oncogene; 2009 Aug; 28(34):3058-68. PubMed ID: 19561646
[TBL] [Abstract][Full Text] [Related]
11. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
12. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
13. The positive feedback loop of NHE1-ERK phosphorylation mediated by BRAF
Li Y; Li D; Liu Y; Wang S; Sun M; Zhang Z; Zheng X; Li J; Li Y
Biochem Biophys Res Commun; 2022 Jan; 588():1-7. PubMed ID: 34933181
[TBL] [Abstract][Full Text] [Related]
14. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.
Hou P; Liu D; Dong J; Xing M
Cell Cycle; 2012 Jan; 11(2):286-95. PubMed ID: 22189819
[TBL] [Abstract][Full Text] [Related]
15. The plasma membrane Ca
Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
17. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
Packer LM; East P; Reis-Filho JS; Marais R
Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
20. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]